Orthofix Medical Inc
$ 12.65
-0.47%
20 Apr - close price
- Market Cap 507,827,000 USD
- Current Price $ 12.65
- High / Low $ 12.82 / 12.50
- Stock P/E N/A
- Book Value 11.30
- EPS -2.33
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.05 %
- ROE -0.19 %
- 52 Week High 16.99
- 52 Week Low 10.24
About
Orthofix Medical Inc. is a medical device and biological products company in the United States, Italy, Germany, the United Kingdom, Brazil, and internationally. The company is headquartered in Lewisville, Texas.
Analyst Target Price
$17.25
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-24 | 2025-11-04 | 2025-08-05 | 2025-05-05 | 2025-03-03 | 2024-11-07 | 2024-08-06 | 2024-05-07 | 2024-03-05 | 2023-11-08 | 2023-08-08 | 2023-05-09 |
| Reported EPS | 0.2378 | -0.57 | -0.36 | -1.3549 | 0.0154 | 0.07 | 0.05 | 0.11 | 0.02 | 0.07 | 0.02 | -0.1 |
| Estimated EPS | -0.22 | -0.33 | -0.41 | -0.2667 | -0.05 | -0.15 | -0.19 | -0.33 | -0.08 | -0.21 | -0.47 | -0.51 |
| Surprise | 0.4578 | -0.24 | 0.05 | -1.0882 | 0.0654 | 0.22 | 0.24 | 0.44 | 0.1 | 0.28 | 0.49 | 0.41 |
| Surprise Percentage | 208.0909% | -72.7273% | 12.1951% | -408.024% | 130.8% | 146.6667% | 126.3158% | 133.3333% | 125% | 133.3333% | 104.2553% | 80.3922% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.73 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OFIX
2026-04-20 20:40:27
Jorge Andres Cedron, CLO of Orthofix Medical Inc. (OFIX), sold 3,743 shares of common stock at $12.82 per share on April 16, 2026. This sale was conducted solely to cover tax withholding obligations related to the settlement of restricted stock units (RSUs), as mandated by a pre-existing "sell-to-cover" requirement. Following the transaction, Cedron retains 59,006 shares, which includes 44,353 previously reported RSUs.
2026-04-20 20:40:27
Orthofix Medical Inc.'s (NASDAQ:OFIX) Chief Legal Officer, Jorge Andres Cedron, sold 3,743 shares of company stock worth $47,985 to satisfy tax withholding obligations. This transaction was part of a pre-approved "sell-to-cover" requirement. Following the sale, Cedron directly holds 59,006 shares, including restricted stock units.
2026-04-20 12:39:17
The provided article content is empty. A summary cannot be generated without content.
2026-04-17 21:00:00
Kahn Swick & Foti, LLC (KSF) has initiated an investigation into Orthofix Medical, Inc. (OFIX) regarding potential breaches of fiduciary duties by its officers and directors. The investigation follows the termination of key executives in September 2023 due to "inappropriate and offensive conduct" and an ongoing securities class action lawsuit against the company. KSF is inviting long-term shareholders to come forward with information to assist their inquiry for potential legal action.
2026-04-13 17:09:07
Kahn Swick & Foti, LLC (KSF) has initiated an investigation into Orthofix Medical, Inc. (NasdaqGS: OFIX) regarding potential breaches of fiduciary duties by its officers and directors. This follows the termination of key executives after an independent investigation revealed inappropriate conduct and a subsequent securities class action lawsuit against the company. KSF is inviting long-term shareholders or individuals with relevant information to contact them regarding their legal rights.
2026-04-10 20:39:58
This page provides a comprehensive overview of Orthofix Med (OFIX) SEC filings, including annual reports (10-K), quarterly reports (10-Q), material event filings (8-K), and insider trading forms (Form 4). It highlights Orthofix's operations as a global medical technology company and explains what information can be found in their regulatory disclosures. The article also presents recent filings, such as an 8-K outlining non-GAAP metrics and several Form 4s detailing director stock grants.
